WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597225
CAS#: 1851348-04-3 (tromethamine)
Description: Pemetrexed tromethamine is a chemotherapy drug. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
Hodoodo Cat#: H597225
Name: Pemetrexed tromethamine
CAS#: 1851348-04-3 (tromethamine)
Chemical Formula: C28H47N7O14
Exact Mass: 0.00
Molecular Weight: 705.710
Elemental Analysis: C, 47.65; H, 6.71; N, 13.89; O, 31.74
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 357166-29-1 (sodium hydrate) 150399-23-8 (disodium) 137281-23-3 (free acid) 357166-30-4 (sodium 2.5 hydrate) 1851348-04-3 (tromethamine)
Synonym: Pemetrexed tromethamine; Pemetrexed ditromethamine dihydrate;
IUPAC/Chemical Name: 2-amino-2-(hydroxymethyl)propane-1,3-diol hemi((4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate) dihydrate
InChi Key: DUORKVZYABUEHW-AHJYMZSGSA-N
InChi Code: 1S/C20H21N5O6.2C4H11NO3.2H2O/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;2*5-4(1-6,2-7)3-8;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);2*6-8H,1-3,5H2;2*1H2/t13-;;;;/m0..../s1
SMILES Code: NC1=Nc2c(C(N1)=O)c(CCc3ccc(C(N[C@H](C(O)=O)CCC(O)=O)=O)cc3)c[nH]2.NC(CO)(CO)CO.NC(CO)(CO)CO.O.O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 705.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Lin L, Zhao J, Hu J, Zou G, Huang F, Han J, He Y, Cao X. Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance. J Cancer. 2018 May 25;9(12):2140-2146. doi: 10.7150/jca.24872. eCollection 2018. PubMed PMID: 29937933; PubMed Central PMCID: PMC6010680.
2: Tang J, Li XY, Liang JB, Wu, Peng L, Li X. Copyright © 2018 Cognizant Communication Corporation. Oncol Res. 2018 Jun 21. doi: 10.3727/096504018X15288447760357. [Epub ahead of print] PubMed PMID: 29929572.
3: Taniguchi Y, Horiuchi H, Morikawa T, Usui K. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. Case Rep Oncol. 2018 May 29;11(2):323-329. doi: 10.1159/000489603. eCollection 2018 May-Aug. PubMed PMID: 29928211; PubMed Central PMCID: PMC6006630.
4: Chapman D, Taj A. Pemetrexed-Induced Syncope. Am J Ther. 2018 Jun 15. doi: 10.1097/MJT.0000000000000803. [Epub ahead of print] PubMed PMID: 29927772.
5: Pangeni R, Choi JU, Panthi VK, Byun Y, Park JW. Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect. Int J Nanomedicine. 2018 Jun 6;13:3329-3351. doi: 10.2147/IJN.S167958. eCollection 2018. PubMed PMID: 29922055; PubMed Central PMCID: PMC5995301.
6: Xu D, Liang SQ, Yang H, Lüthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. Br J Cancer. 2018 Jun 20. doi: 10.1038/s41416-018-0145-3. [Epub ahead of print] PubMed PMID: 29921948.
7: Xu H, Xu F, Zhu W, Ying J, Wang Y. Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. Thorac Cancer. 2018 Jun 19. doi: 10.1111/1759-7714.12777. [Epub ahead of print] PubMed PMID: 29917332.
8: Petri GL, Cascioferro S, Parrino B, Peters GJ, Diana P, Giovannetti E. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma. Pharmacogenomics. 2018 Jun 19. doi: 10.2217/pgs-2018-0071. [Epub ahead of print] PubMed PMID: 29916298.
9: Müller C, Guzik P, Siwowska K, Cohrs S, Schmid RM, Schibli R. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates. Molecules. 2018 Jun 16;23(6). pii: E1465. doi: 10.3390/molecules23061465. PubMed PMID: 29914162.
10: Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol. 2018 Jun;25(Suppl 1):S45-S58. doi: 10.3747/co.25.3747. Epub 2018 Jun 13. Review. PubMed PMID: 29910647; PubMed Central PMCID: PMC6001774.
11: Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x. PubMed PMID: 29909581.
12: Carneiro-Leão L, Barzylovych V, Cernadas J. Pemetrexed anaphylaxis - an unusual suspect. J Allergy Clin Immunol Pract. 2018 Jun 13. pii: S2213-2198(18)30392-1. doi: 10.1016/j.jaip.2018.06.004. [Epub ahead of print] PubMed PMID: 29908333.
13: Mahmud F, Jeon OC, Alam F, Maharjan R, Choi JU, Park J, Lee S, Park JW, Lee DS, Byun Y. Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. J Control Release. 2018 Jun 13. pii: S0168-3659(18)30364-X. doi: 10.1016/j.jconrel.2018.06.018. [Epub ahead of print] PubMed PMID: 29908222.
14: Laslett NF, Park S, Masters GA, Biggs DD, Schneider CJ, Misleh JG, Suppiah K, Simpson PS, Grubbs S, Wozniak TF, Guarino M. Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1569. [Epub ahead of print] PubMed PMID: 29905018.
15: Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, Lubiniecki GM, Carbone DP. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study. Clin Lung Cancer. 2018 May 7. pii: S1525-7304(18)30099-8. doi: 10.1016/j.cllc.2018.04.017. [Epub ahead of print] PubMed PMID: 29885945.
16: Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30673-7. doi: 10.1016/j.jtho.2018.05.026. [Epub ahead of print] PubMed PMID: 29883837.
17: Thawani R, Thomas A, Thakur K. Tracheomediastinal Fistula: Rare Complication of Treatment with Bevacizumab. Cureus. 2018 Apr 3;10(4):e2419. doi: 10.7759/cureus.2419. PubMed PMID: 29872599; PubMed Central PMCID: PMC5985921.
18: Hill J, Vargo C, Smith M, Streeter J, Carbone DP. Safety of dose-reduced pemetrexed in patients with renal insufficiency. J Oncol Pharm Pract. 2018 Jan 1:1078155218780507. doi: 10.1177/1078155218780507. [Epub ahead of print] PubMed PMID: 29871545.
19: Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C, Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A, D'Arca D, Ferrari S, Costi MP. Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. Front Pharmacol. 2018 May 8;9:454. doi: 10.3389/fphar.2018.00454. eCollection 2018. PubMed PMID: 29867465; PubMed Central PMCID: PMC5952181.
20: Baxevanos P, Mountzios G. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? Ann Transl Med. 2018 Apr;6(8):139. doi: 10.21037/atm.2018.04.04. Review. PubMed PMID: 29862228; PubMed Central PMCID: PMC5952027.
